First treatment for molluscum contagiosum wins FDA approval

Ycanth (cantharadin), indicated for the topical treatment of molluscum contagiosum in adult and pediatric patients ≥2 years of age, is administered by health care providers every 3 weeks as needed. Approval was based on data from two phase 3 RCTs (CAMP-1 and Camp-2), in which 54% of participants treated with Ycanth achieved complete clearance of all treated molluscum bumps by day 84 vs. 13% of those treated with placebo.